An interventional study of Oxiconazole Nitrate Cream and Clotrimazole Cream in Dermatophytoses, sponsored by Shalamar Institute of Health Sciences. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Shalamar Institute of Health Sciences · Not applicable, Interventional, and Treatment
To compare the efficacy of oxiconazole 1 % cream and clotrimazole cream for treatment of dermatophytosis
Following approval from the hospital ethical committee, informed consent will be obtained from all patients, with basic information including name, age, gender, baseline clinical score, and location of dermatophytosis noted. A total of 164 patients will be evenly divided into two groups, each comprising 82 patients, utilizing a lottery method. In Group A, 1% oxiconazole cream will be applied once daily on skin lesions, while in Group B, 1% clotrimazole cream will be applied twice daily on the affected skin area. Tab. certirizine 10mg will be taken by patients of both groups at night for itching. The treatment will be continued for 1 month, and patients will do follow up visit at 2nd and 4th week from baseline. The clinical score will be assessed and photographs will be taken at each visit. Clinical assessment score will be will be made on the parameters of erythema, pruritus, and scaling, ranging from 0 (absent) to 3 (severe) for each parameter, with a maximum total score of 9.
Exclusion Criteria:
Group participants will receive oxiconazole cream treatment
Drug: Oxiconazole Nitrate Cream
Group participants will receive clotrimazole cream treatment
Drug: Clotrimazole Cream
Oxiconazole 1 % cream will be applied on dermatophytosis lesions
Clotrimazole cream will be applied to clotrimazole group on dermatophytosis lesions
Efficacy in terms of clearance of lesions , pruritis and scaling
Efficacy as complete clinical cure at the conclusion of the treatment period. Complete clinical cure will be considered 0 score on Clinical Assessment Score (CAS). Clinical Assessment Score: It will be assessed on the parameters of erythema, pruritus, and scaling, ranging from 0 (absent) to 3 (severe) for each parameter, with a maximum total score of 9.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shalamar Institute of Health Sciences